Loading...
Market
Which region will first approve GSK's CMG1A46 by end of 2026?
2
Resolution / Starting Odds
United States • 25%
European Union • 25%
China • 25%
Other • 25%
Regulatory body announcements and GSK press releases
Story
British GSK Acquires Experimental Lupus Drug from Chimagen Biosciences for Up to $850 Million
Oct 29, 2024, 12:27 PM
British drugmaker GSK has entered into an agreement to acquire CMG1A46, an experimental drug from Chinese biotech firm Chimagen Biosciences, for up to $850 million. This acquisition includes a $300 million upfront payment and aims to expand GSK's pipeline of potential treatments for lupus. The drug, CMG1A46, is a clinical-stage dual CD19 and CD20-targeted T cell-engager, which is expected to enhance GSK's immunology portfolio.
View original story
Similar markets
United States • 25%
European Union • 25%
China • 25%
Other • 25%
United States • 25%
European Union • 25%
China • 25%
Other • 25%
United States • 25%
European Union • 25%
China • 25%
Other • 25%
United States • 25%
European Union • 25%
China • 25%
Other • 25%
United States • 25%
European Union • 25%
Asia-Pacific • 25%
Other regions • 25%
European Union • 25%
United Kingdom • 25%
Australia • 25%
Other • 25%
Europe • 25%
United States • 25%
Asia • 25%
Other • 25%
United States • 25%
United Kingdom • 25%
Germany • 25%
Other • 25%
United States • 25%
European Union • 25%
Africa • 25%
Other • 25%
Europe • 25%
Asia • 25%
South America • 25%
Other • 25%
Japan • 25%
USA • 25%
EU • 25%
Other • 25%
USA • 25%
EU • 25%
UK • 25%
Other • 25%